Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Novavax Stock Falls on Report of Covid Vaccine Production Problems

Published 21/10/2021, 02:24 am
Updated 21/10/2021, 02:24 am
© Reuters

© Reuters

By Sam Boughedda

Investing.com —  Novavax (NASDAQ:NVAX) shares tumbled 9.9% Wednesday following a report from Politico that the drug maker has run into delays regarding the production of its Covid-19 vaccine. 

The report said that Novavax has faced problems concerning the testing of the purity of its vaccine candidate and that it has so far failed to prove the shot is "consistently up to snuff."

According to the Politico report, which cites people familiar with the  matter, the practices used to test the vaccine's efficacy have dropped below U.S. regulators’ standards.

However, Novavax has since come out and expressed confidence in its vaccine candidate and manufacturing. "In response to a recent news article citing anonymous sources, Novavax confirms our confidence in our ability to deliver our high-quality vaccine. Further, we underscore our ongoing commitment to the stringent standards of production and manufacturing for our recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant," the company said.

The company continued by saying that it has "made significant progress in mobilizing a global manufacturing network over the past 18 months with sites that are now routinely producing high-quality product at commercial scale at multiple sites across the world. Our global supply chain is expected to achieve a capacity of 150 million doses per month by the end of the fourth quarter."

In addition, Novavax said it sees regulatory submissions within the next couple of weeks in some of its key markets, including the United Kingdom, Europe, Canada, Australia, and New Zealand. 

It has already, along with its partner SII, filed for authorization in India, Indonesia, The Philippines, and Emergency Use Listing with the World Health Organization. They also expect to file for Emergency Use Authorization in the U.S. before the end of this year.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.